Navigation Links
Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease

IRVING, Texas, Nov. 11, 2010 /PRNewswire/ -- Reata Pharmaceuticals today announced that the company will present data on the primary endpoint from a pivotal Phase 2b clinical trial of bardoxolone methyl in patients with chronic kidney disease (CKD) and type 2 diabetes. The data will be presented in a late-breaking oral presentation at the American Society of Nephrology (ASN) Renal Week Conference to be held November 16-21, 2010, in Denver, Colorado.

Pablo Pergola, M.D., Ph.D., Research Director for Renal Associates PA and Clinical Associate Professor of Medicine at the University of Texas Health Science Center at San Antonio, will deliver the presentation titled, "Effect of Bardoxolone Methyl on Renal Function in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus" at 10:55 a.m. MST on Saturday, November 20, in the Wells Fargo Theater at the Denver Convention Center.

The multi-center, randomized, double-blind clinical trial enrolled 227 CKD patients who were randomized to receive once-daily doses of placebo or 25, 75 or 150 mg doses of bardoxolone methyl. The primary endpoint of the study was change in kidney function following 24 weeks of treatment.

ASN has not released complete abstracts for late-breaking presentations, but the title and complete list of authors of the abstract can be accessed on the ASN Web site.

In addition to the late-breaking presentation, Reata and its collaborators will present additional preclinical data from the program in poster sessions to be held between 10 a.m. and 2:30 p.m. MST on Thursday, November 18 and Friday, November 19. The titles and presenters of those posters are as follows:

"Bardoxolone methyl activates Keap1-Nrf2 and increases glutathione levels in cultured cells" by Ron Bumeister, Ph.D., Senior Scientist, Reata Pharmaceuticals

"Bardoxolone methyl improves markers of endothelial function in cultured cells" by Deborah A. Ferguson, Ph.D., Director, Discovery Biology, Reata Pharmaceuticals

"Treatment with Nrf2 activator ameliorates uremia-induced oxidative stress, endothelial dysfunction, and hypertension" by Stanislav Shelkovnikov, Ph.D., Associate Researcher, University of California, Irvine

"Treatment with an AIM increases GFR monitored by inulin clearance in rats" by W. Christian Wigley, Ph.D., Vice President, Research, Reata Pharmaceuticals

"Targeting Keap1-Nrf2 pathway ameliorates renal inflammation and fibrosis in mice with protein-overload proteinuria" by Carlamaria Zoja, Ph.D., Head, Laboratory of Experimental Models of Kidney Diseases, Mario Negri Institute for Pharmacological Research

"Effects of bardoxolone methyl on renal protein handling and secondary nephropathy" by Irina Dulubova, Ph.D., Director, Biochemistry and Structural Biology, Reata Pharmaceuticals

About Bardoxolone Methyl

Bardoxolone methyl is an antioxidant inflammation modulator (AIM) that activates Nrf2, thereby inducing the transcription of more than 250 genes that decrease the level of oxidative stress and suppress important inflammatory mediators.  In two Phase 2a studies, bardoxolone methyl was shown to produce a statistically significant increase in kidney function in patients with moderate to severe CKD and Type 2 diabetes.

About Chronic Kidney Disease and Diabetic Kidney Disease (Nephropathy)

CKD is a highly prevalent condition, affecting more than 50 million adults around the world.  Diabetes is the leading cause of CKD, with as many as 30 to 40 percent of Type 2 diabetics developing the disease.  Available therapies modestly slow the progression of CKD, and patients ultimately progress to dialysis.

About Reata Pharmaceuticals

Reata Pharmaceuticals is the leader in discovering and developing novel, oral anti-inflammatory drugs that activate Nrf2, the primary regulator of cellular antioxidant and detoxification enzymes.  Activation of this important biological target protects against a broad range of diseases associated with inflammation and oxidative stress.  Reata is developing bardoxolone methyl, its lead product candidate, for the treatment for chronic kidney disease.  In January 2010, Reata and Kyowa Hakko Kirin announced a licensing agreement providing KHK with the exclusive rights to develop and commercialize bardoxolone in Japan and other selected Asian markets. In September 2010, Reata formed a strategic partnership with Abbott for the commercialization of bardoxolone in other ex-U.S. markets.  Reata retains exclusive rights to bardoxolone in the U.S.

For more information please visit the company's Web site at

Contact: Heidi Chokeir, 619-528-2217,

SOURCE Reata Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
2. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
3. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
4. Arbor Pharmaceuticals Completes $34.8 Million Financing
5. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for First Quarter Fiscal 2011
6. Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company
7. Access Pharmaceuticals Presents CobOral™ Insulin Research at 10th Annual Diabetes Technology Meeting on November 11-13, 2010
8. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
9. DUSA Pharmaceuticals to Present at the 4th Annual Maxim Group Growth Conference
10. Omthera Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
11. Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
(Date:11/29/2015)... , Nov. 29, 2015  Strengthening its leadership ... PHG, AEX: PHIA) today announced IntelliSpace Portal 8.0 ... analytics and visualization platform that helps radiologists detect, diagnose ... 2015 Radiological Society of North America Annual Meeting ... IntelliSpace Portal 8.0 helps address the changing demands in ...
(Date:11/29/2015)... , Nov. 29, 2015  At this year,s ... to experience the most complete mobile C-arm portfolio with ... is Ziehm Vision RFD 3D, the world,s only 3D ... edge length per scan volume. In addition, Ziehm Imaging ... motorized mobile C-arm in four axes which is ideally ...
(Date:11/29/2015)... 29, 2015 CIVCO Medical Solutions will ... the Radiological Society of North America ... November 29 – December 4, 2015. ... offer customers unrivaled versatility, enhanced user experience and ... --> ...
Breaking Medicine Technology:
(Date:11/30/2015)... VA (PRWEB) , ... November 30, 2015 , ... ... Association of Poison Control Centers’ National Poison Data System (NPDS) reveals that in ... managed almost 3 million cases, over two million of which were human exposure ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... their exclusive channel partner for the Nutraceutical Specialties products into oral solid dosage ... effective immediately. , “We are pleased to announce our expanded distribution agreement ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... Solutions, announced at the Radiology Society of North America (RSNA) annual meeting, being ... over 60% growth from 2014. Throughout 2015, the company has completed installations ...
(Date:11/30/2015)... ... 30, 2015 , ... Holcomb – Kreithen Plastic Surgery ... practices in Florida, is proud to announce that Dr. Joshua Kreithen, one of ... Inc., a Johnson & Johnson Company. , Ethicon is a global medical device ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. and Novus ... technology for soft tissue repair in the US via Insightra’s national direct sales ... mesh intended to support and reinforce soft tissue for 6-9 months before absorbing ...
Breaking Medicine News(10 mins):